Regeneron Fights Sandoz Eylea Patent-Misconduct Claims (Correct)

Regeneron Pharmaceuticals Inc. urged a West Virginia federal judge to dismiss Sandoz Group AG’s claims it misled the US Patent and Trademark Office during the Eylea patent-application process.

Regeneron sued Sandoz on Aug. 26 seeking damages and an order blocking Enzeevu, a recently approved biosimilar version of its blockbuster eye-disease drug Eylea that it said infringes 46 patents. Sandoz countered that Regeneron misled the USPTO while prosecuting three of the patents—US Patent Nos. 10,828,345, 11,459,374, and 11,975,045—by making false and misleading statements about material references and failing to disclose critical information.

Sandoz also alleged, “without elaboration and ...